These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 7763093)

  • 1. Clinical relevance of cathepsin B-like enzyme activity and cysteine proteinase inhibitor in melanocytic tumours.
    Yoshii A; Kageshita T; Tsushima H; Ono T
    Arch Dermatol Res; 1995; 287(2):209-13. PubMed ID: 7763093
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biochemical and immunohistochemical analysis of cathepsins B, H, L and D in human melanocytic tumours.
    Kageshita T; Yoshii A; Kimura T; Maruo K; Ono T; Himeno M; Nishimura Y
    Arch Dermatol Res; 1995; 287(3-4):266-72. PubMed ID: 7598531
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inducible nitric oxide synthase expression in benign and malignant cutaneous melanocytic lesions.
    Massi D; Franchi A; Sardi I; Magnelli L; Paglierani M; Borgognoni L; Maria Reali U; Santucci M
    J Pathol; 2001 Jun; 194(2):194-200. PubMed ID: 11400148
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cathepsin B to cysteine proteinase inhibitor balance in metastatic cell subpopulations isolated from murine tumors.
    Rozhin J; Gomez AP; Ziegler GH; Nelson KK; Chang YS; Fong D; Onoda JM; Honn KV; Sloane BF
    Cancer Res; 1990 Oct; 50(19):6278-84. PubMed ID: 2400991
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of In Vivo Reflectance Confocal Microscopy in the Analysis of Melanocytic Lesions.
    Serban ED; Farnetani F; Pellacani G; Constantin MM
    Acta Dermatovenerol Croat; 2018 Apr; 26(1):64-67. PubMed ID: 29782304
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of cyclooxygenase-2 in benign naevi and during human cutaneous melanoma progression.
    Kuźbicki L; Sarnecka A; Chwirot BW
    Melanoma Res; 2006 Feb; 16(1):29-36. PubMed ID: 16432453
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deep penetrating nevus-like borderline tumors: A unique subset of ambiguous melanocytic tumors with malignant potential and normal cytogenetics.
    Magro CM; Abraham RM; Guo R; Li S; Wang X; Proper S; Crowson AN; Mihm M
    Eur J Dermatol; 2014; 24(5):594-602. PubMed ID: 25118781
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An inactive cathepsin B-like enzyme and cysteine proteinase inhibitors in colon cancer ascites.
    Matsuoka Y; Tsushima H; Koga Y; Mihara H; Hopsu-Havu VK
    Neoplasma; 1992; 39(2):107-14. PubMed ID: 1528307
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Surface microscopy of naevi and melanomas--clues to melanoma.
    Nilles M; Boedeker RH; Schill WB
    Br J Dermatol; 1994 Mar; 130(3):349-55. PubMed ID: 8148277
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cathepsins B, H, L and cysteine protease inhibitors in malignant prostate cell lines, primary cultured prostatic cells and prostatic tissue.
    Friedrich B; Jung K; Lein M; Türk I; Rudolph B; Hampel G; Schnorr D; Loening SA
    Eur J Cancer; 1999 Jan; 35(1):138-44. PubMed ID: 10211102
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclooxygenase-2 (COX-2): first immunohistochemical marker distinguishing early cutaneous melanomas from benign melanocytic skin tumours.
    Chwirot BW; Kuźbicki Ł
    Melanoma Res; 2007 Jun; 17(3):139-45. PubMed ID: 17505259
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Properties of a plasma membrane-associated cathepsin B-like cysteine proteinase in metastatic B16 melanoma variants.
    Rozhin J; Robinson D; Stevens MA; Lah TT; Honn KV; Ryan RE; Sloane BF
    Cancer Res; 1987 Dec; 47(24 Pt 1):6620-8. PubMed ID: 2824039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The dermoscopic classification of atypical melanocytic naevi (Clark naevi) is useful to discriminate benign from malignant melanocytic lesions.
    Blum A; Soyer HP; Garbe C; Kerl H; Rassner G; Hofmann-Wellenhof R
    Br J Dermatol; 2003 Dec; 149(6):1159-64. PubMed ID: 14674892
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of SOX10, ABCB5 and CD271 in melanocytic lesions and correlation with survival data of patients with melanoma.
    Gambichler T; Petig AL; Stockfleth E; Stücker M
    Clin Exp Dermatol; 2016 Oct; 41(7):709-16. PubMed ID: 27663144
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Matrix metalloproteinase-2 (72 kD type IV collagenase) expression occurs in the early stage of human melanocytic tumour progression and may have prognostic value.
    Väisänen A; Tuominen H; Kallioinen M; Turpeenniemi-Hujanen T
    J Pathol; 1996 Nov; 180(3):283-9. PubMed ID: 8958806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Nevus associated malignant melanomas--diagnostic validation and prognosis].
    Stadler R; Garbe C
    Hautarzt; 1991 Jul; 42(7):424-9. PubMed ID: 1938395
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of cell surface cathepsin B-like activity on murine melanomas and fibrosarcomas: modulation by butanol extraction.
    Keren Z; LeGrue SJ
    Cancer Res; 1988 Mar; 48(6):1416-21. PubMed ID: 3345513
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of Patient Risk Factors and Frequency of Nevus-Associated Cutaneous Melanomas.
    Haenssle HA; Mograby N; Ngassa A; Buhl T; Emmert S; Schön MP; Rosenberger A; Bertsch HP
    JAMA Dermatol; 2016 Mar; 152(3):291-8. PubMed ID: 26536613
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epiluminescence microscopy features of cutaneous malignant melanoma metastases.
    Schulz H
    Melanoma Res; 2000 Jun; 10(3):273-80. PubMed ID: 10890382
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Distribution and colocalization of markers for proliferation, invasion, motility and neoangiogenesis in benign melanocytic naevi and malignant melanomas.
    Fröhlich E; Mack AF; Garbe C; Klessen C
    Br J Dermatol; 2005 Dec; 153(6):1159-65. PubMed ID: 16307652
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.